Influenza antigen delivery vectors and constructs
AssigneeAltimmune UK Limited
InventorsDominique Bonnet, Carlton Brown, Bertrand Georges, Philip Sizer
Life of this patent
Estimating the term…
Abstract
The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
Claims15
1-33. (canceled)
A vector-peptide construct comprising:
- an immunogenic influenza peptide sequence covalently attached to a vector for intracellular delivery of the peptide, wherein the vector comprises structure CmXn—CyHx-(Sp)-R, wherein m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety, R is the immunogenic influenza peptide covalently linked via a terminal lysine to the vector and X is selected from a fluorine, chlorine, bromine or iodine;
- and wherein the immunogenic influenza peptide is up to 40 amino acids in length and comprises one or more CD8+ T cell epitopes and one or more CD4+ T cell epitopes.
A pharmaceutical composition for intracellular delivery of an immunogenic peptide, the composition comprising an immunogenic influenza peptide sequence covalently attached to a vector for intracellular delivery of the peptide, wherein the vector comprises structure CmXn—CyHx-(Sp)-R, wherein m=3 to 30, n<=2m 1, y=0 to 15, x<=2y, (m+y)=3 to 30, Sp is an optional chemical spacer moiety, R is the immunogenic influenza peptide covalently linked via a terminal lysine to the vector and X is selected from a fluorine, chlorine, bromine or iodine;
- and wherein the immunogenic influenza peptide is up to 40 amino acids in length and comprises one or more CD8+ T cell epitopes and one or more CD4+ T cell epitopes.
Dependencies are inferred from the claim text.